ERBB2 and ductal breast carcinoma in situ: To facilitate potential de-escalation of surgery in the future in this patient group, we aim to estimate the response of adjacent DCIS to NST containing HER2-blockade in a large series of HER2-positive breast cancer patients and to identify clinicopathological and radiological factors that predict response.